The objective: to allocate the clinico-anamnestic and hormonal and metabolic indicators influencing the remote results of treatment Spironolactonum. Materials and methods. 78 girls at the age of 13–17.5 years with a hypomenstrual syndrome are surveyed (НMS: an oligomenorrhea – OHM, a secondary amenorrhea – VA) in 2 years and more after an initiation of treatment Spironolactonum (3 ten-day courses). The menstrual age (MA), the perinatal anamnesis, НMS duration prior to treatment, the index of body weight (IBW), uterus volume according to ultrasonic examination (US) of organs of a small pelvis, degree of expression of a hirsutism, contents in a cow of gonadotrophic, sex hormones, рrolactinum (PRL), insulin were studied by an immunoenzymatic method. The prognostic coefficient (PC) and its informational content were defined (I). The criterion of efficiency of treatment is an independent regular menstrual cycle. Results. The remote efficiency of treatment at OHM reached 62.9%, at VA – only 20.1% (Р < 0.001). The most prognostically significant relatively positive takes of treatment is the MV up to 2 years (PC = +5.13; I = 0.542), rather negative results – VA (PC = - 3.54; I = 0.545), a hirsutism of the II–III Art. on Ferrimana-Gаlvey’s scale, the increased LG level (PC = - 3.52; I = 0.59) and the lowered contents in blood estradiolum (PC = - 3.68; I = 0.36). Conclusions. The separated efficiency of treatment Spironolactonum within three months is 3 times better at OHM, than at VA. Girls with НMS demand inspection and treatment in the first 1–1.5 years after a menarche. Special attention should be paid to girls with the expressed hirsutism, to at what disorders of menstrual function remain within 2 years and more, with the LG high initial level and the lowered content in blood estradiolum. Key words: teenage girls, hypomanstrual syndrome, spironolactone, long-term effectiveness, гирсутизм, estradiol.